Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Patellar Tendon Regeneration With Platelet-rich Plasma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01111747
Recruitment Status : Completed
First Posted : April 28, 2010
Last Update Posted : March 14, 2012
Sponsor:
Collaborator:
Instituto de Ortopedia e Traumatologia - HCFMUSP - São Paulo, Brazil
Information provided by (Responsible Party):
University of Sao Paulo General Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The central third of the patellar tendon is used as a donor site for anterior cruciate ligament (ACL) reconstruction. After months or years the harvest site partially regenerates. The regeneration process is accomplished by biological mechanisms,including cells and proteins known as growth factors. The platelets are natural reservoirs of growth factors, and a platelet concentrate known as Platelet-Rich Plasma (PRP) has a three to five fold increase in growth factors. The hypothesis of the study is that the PRP can improve the regeneration of the patellar tendon.

The platelets are obtained from the patient's blood through a filtration system called apheresis, with the use of 250 milliliters of blood, with a sterile system. All the others components of blood (red cells, plasma, white cells) returns to the patient. The PRP is then applied in the harvest site on the patellar tendon, at the end of ACL reconstruction.

The patients are randomized in two groups, one with the use of PRP and the other group without PRP. This information for the patients will be granted just at the end of the research. After the surgery the rehabilitation protocol is the same for both groups. An isokinetic testing is done before the surgery and after six months. Questionnaires about the knee function are asked before the surgery and after six months. A magnetic resonance imaging is performed after six months to evaluate the tendon regeneration.


Condition or disease Intervention/treatment Phase
Knee Instability Procedure: Platelet-rich plasma Procedure: Control group Phase 4

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Regeneration of the Patellar Tendon After Harvesting Its Central Third With Platelet-rich Plasma. Prospective and Randomized Study.
Study Start Date : November 2008
Actual Primary Completion Date : July 2010
Actual Study Completion Date : December 2010
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: PRP
In this group PRP will be used in the patellar tendon donor site.
 Procedure: Platelet-rich plasma
Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
Other Names:
  • PRP
  • platelet gel
  • platelet concentrate
  • growth factors concentrate
  • plasma rich in growth factors
Sham Comparator: Control
In this group PRP will not be aded to the patellar tendon donor site
 Procedure: Control group
In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
Other Names:
  • PRP
  • platelet-rich plasma
  • platelet gel
  • platelet concentrate
  • growth factors concentrate
  • plasma rich in growth factors


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Evaluation of the patellar tendon regeneration with magnetic resonance imaging. [ Time Frame: Six months ]
    Six months after the surgery a magnetic resonance imaging will be done to evaluate the regeneration of the patellar tendon donor site. The area of the gap, related to the tendon harvest, will be measured and compared between the groups.


Secondary Outcome Measures :
  1. Isokinetic testing and questionaires. [ Time Frame: Six months ]
    Six months after the surgery, patients will answer to questionaires about their knee function and do an isokinetic testing to evaluate their muscle strength. The results will be compared between the groups.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • indication of anterior cruciate ligament surgery with patellar ligament
  • skeletal maturity

Exclusion Criteria:

  • other knee ligament injuries
  • severe chondral lesions
  • osteoarthritis
  • non-compliance to the rehabilitation
  • previous surgery in the affected knee
  • reoperation during the time of the study for an unrelated condition
  • infection
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01111747


Sponsors and Collaborators
University of Sao Paulo General Hospital
Instituto de Ortopedia e Traumatologia - HCFMUSP - São Paulo, Brazil
Investigators
Layout table for investigator information
Principal Investigator: Adriano M Almeida, MD Instituto de Ortopedia e Traumatologia - HCFMUSP - São Paulo, Brazil
Study Director: Arnaldo J Hernandez, MD, PhD Instituto de Ortopedia e Traumatologia - HCFMUSP - São Paulo, Brazil
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications:

Layout table for additonal information
Responsible Party: University of Sao Paulo General Hospital
ClinicalTrials.gov Identifier: NCT01111747     History of Changes
Other Study ID Numbers: 0162/08
CaPPesqHCFMUSP 0162/2008 ( Other Identifier: São Paulo University )
First Posted: April 28, 2010    Key Record Dates
Last Update Posted: March 14, 2012
Last Verified: April 2010
Keywords provided by University of Sao Paulo General Hospital:
platelet-rich plasma
patellar ligament
regeneration
growth substances
Additional relevant MeSH terms:
Layout table for MeSH terms
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action